Ransdell Pierson – Page 12

Bristol’s patent woes persist despite Amylin buy

December 24, 2018 at 8:29 a.m.

(Reuters) - Bristol-Myers Squibb Co stands to become a stronger player in diabetes through its expensive acquisition of Amylin Pharmaceuticals Inc but its earnings and pricy shares remain vulnerable to...

Survey shows dim faith in Lilly, Pfizer Alzheimer’s drugs

August 23, 2021 at 9:39 a.m.

(Reuters) - Institutional investors doubt that treatments for Alzheimer's disease being developed by Pfizer Inc and Eli Lilly will achieve the main goals of their ongoing late-stage trials, but hopes...

Survey shows dim faith in Lilly, Pfizer Alzheimer’s drugs

May 13, 2019 at 6:58 p.m.

(Reuters) - Institutional investors doubt that treatments for Alzheimer's disease being developed by Pfizer Inc and Eli Lilly will achieve the main goals of their ongoing late-stage trials, but hopes...

Insight: Top heart doctors fret over new blood thinners

August 23, 2021 at 9:14 a.m.

NEW YORK (Reuters) - For millions of heart patients, a pair of new blood thinners have been heralded as the first replacements in 60 years for warfarin, a pill whose...

Insight: Top heart doctors fret over new blood thinners

May 13, 2019 at 6:48 p.m.

NEW YORK (Reuters) - For millions of heart patients, a pair of new blood thinners have been heralded as the first replacements in 60 years for warfarin, a pill whose...

Johnson & Johnson now expects Synthes deal to boost profit

August 23, 2021 at 9:12 a.m.

By Ransdell Pierson (Reuters) - Johnson & Johnson said it expects to complete its $19.7 billion purchase of Swiss medical device maker Synthes on Thursday and that the deal will...

Johnson & Johnson now expects Synthes deal to boost profit

December 24, 2018 at 6:51 a.m.

By Ransdell Pierson (Reuters) - Johnson & Johnson said it expects to complete its $19.7 billion purchase of Swiss medical device maker Synthes on Thursday and that the deal will...

Johnson & Johnson plans $600 million charge linked to Risperdal sales

August 23, 2021 at 8:56 a.m.

(Reuters) - Johnson & Johnson said on Friday it expects to take a special charge of about $600 million in the second quarter to bolster reserves for a potential settlement...

Johnson & Johnson plans $600 million charge linked to Risperdal sales

May 13, 2019 at 6:41 p.m.

(Reuters) - Johnson & Johnson said on Friday it expects to take a special charge of about $600 million in the second quarter to bolster reserves for a potential settlement...

UNICEF targets deadly diarrhea, pneumonia in poor kids

August 23, 2021 at 8:59 a.m.

NEW YORK (Reuters) - Concerted efforts to control diarrhea and pneumonia, the biggest killers of children under the age of five, could save the lives of up to 2 million...

All Stories